Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D3 Supplementation in First Episode Schizophrenia
NCT03101319Completed
- Sponsor
- Central Institute of Psychiatry
- Start
- Apr 2019
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, double-blind trial of vitamin d in schizophrenia (2 arms), sponsored by Central Institute of Psychiatry. Primary endpoints: Positive and Negative Syndrome Scale at 8 weeks and Computerized Neurocognitive Battery at 8 weeks. Started Apr 2019; status: completed.
02
Drugs
vitamin d
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03101319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101319.